Can I integrate ketamine into my clinical practice?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed physicians, nurse practitioners, physician assistants, and other prescribing clinicians who want to understand the legal framework for offering ketamine or esketamine as part of their clinical practice.

The short answer

Yes — ketamine is a DEA Schedule III controlled substance, not Schedule I, and its use in clinical practice is legally distinct from psilocybin in every significant way. Esketamine (Spravato) is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, and clinicians who want to offer it must comply with the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, which requires a certified clinical setting and specific monitoring protocols. IV ketamine for depression is legal as an off-label use of a Schedule III substance — there is no FDA approval for this indication, but off-label prescribing is lawful, and this is how the majority of ketamine infusion clinics in the United States operate. The legal questions for a clinician considering ketamine are about regulatory compliance, DEA registration, state prescribing authority, and standard of care — not about federal illegality.

Ketamine’s legal status

Ketamine was placed on DEA Schedule III in 1999. Schedule III controlled substances have accepted medical uses and a moderate potential for abuse — a materially different category from psilocybin’s Schedule I, which carries no currently accepted medical use under federal law. A clinician with DEA prescribing authority can prescribe ketamine within their scope of practice and in compliance with applicable state law. No separate federal authorization beyond standard DEA registration is required to prescribe ketamine off-label.

This means the federal legal calculus for ketamine is entirely different from psilocybin. A clinician who prescribes IV ketamine for depression is engaged in lawful off-label prescribing of a scheduled substance with a legitimate medical use — not in conduct that implicates the Controlled Substances Act’s prohibitions on Schedule I substances.

Esketamine (Spravato): the FDA-approved pathway

Esketamine is the S-enantiomer of ketamine, formulated as a nasal spray by Janssen Pharmaceuticals under the brand name Spravato. It received FDA approval in March 2019 for treatment-resistant depression (TRD) in adults, and in August 2020 for major depressive disorder with acute suicidal ideation or behavior (MDD-ASIB). It is the first FDA-approved drug with a novel mechanism of action for depression in decades, and the only ketamine formulation with an FDA-approved indication for any psychiatric condition.

Because of abuse and misuse potential, the FDA requires esketamine to be dispensed and administered under a REMS program. The REMS requirements are specific: esketamine must be dispensed only to patients enrolled in the REMS program, must be administered in a certified healthcare setting by a certified healthcare provider, and patients must be monitored in that setting for at least two hours after each dose due to risks of sedation, dissociation, and misuse. Patients cannot take esketamine home. Self-administration is not permitted.

A clinician who wants to offer esketamine must certify their facility and enroll in the REMS program through the FDA. The certification process involves training, facility requirements (monitoring equipment, the ability to manage sedation and cardiovascular events), and documentation obligations. A clinician operating outside the REMS framework is violating the FDA approval conditions, which creates both regulatory and malpractice exposure.

Insurance coverage for Spravato is more available than for any other psychedelic-adjacent treatment. Most major commercial insurers cover esketamine for TRD following failure of adequate antidepressant trials. Medicare Part B covers Spravato administered in a certified facility (approximately 80% after the Part B deductible, which was $257 in 2025). Many Medicaid plans cover it as well, subject to prior authorization. Coverage requirements vary by payer and typically require documentation of prior antidepressant treatment failures.

IV ketamine: the off-label pathway

Intravenous ketamine for depression, anxiety, PTSD, and chronic pain is widely offered by ketamine infusion clinics across the United States. This is legal off-label prescribing — the FDA has not approved IV ketamine for these indications, but off-label use of approved drugs is lawful. The relevant legal framework is the standard one for off-label prescribing: the prescribing clinician must have a legitimate clinical basis for the use, must obtain informed consent that includes disclosure of the off-label status, and must maintain documentation consistent with the standard of care.

Because IV ketamine is not FDA-approved for depression, it is not covered by Medicare, Medicaid, or most commercial insurers for psychiatric indications. It is almost entirely cash-pay, with a typical course of six infusions running between $2,400 and $6,400. Some insurers cover IV ketamine for pain management, which has a longer history of off-label use, but psychiatric indications are generally excluded.

The standard of care for IV ketamine for depression is not formally established by any professional association as of early 2026. The American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) and the American Psychiatric Association have published consensus guidance and position statements that inform what reasonable practice looks like, but neither constitutes a binding clinical standard. A clinician offering IV ketamine should be aware that expert witnesses in malpractice cases will look to these documents as evidence of what careful practitioners do.

DEA registration and state prescribing authority

A clinician who wants to prescribe ketamine — whether for a certified esketamine program or as off-label IV use — must hold an active DEA registration that covers Schedule III controlled substances. Most clinicians with prescribing authority already have this registration. Ketamine prescribing authority also depends on state scope of practice law: in states where nurse practitioners or physician assistants have full prescribing authority, they can prescribe ketamine within that authority; in states with more restrictive scope of practice requirements, additional supervision or collaboration arrangements may apply.

Some states have enacted specific regulations governing ketamine clinics — addressing facility requirements, prescriber qualifications, patient monitoring standards, and record-keeping. A clinician considering opening a ketamine practice should review their state’s specific requirements before establishing a clinic, not assume that DEA registration and off-label prescribing authority are sufficient.

The prescribing relationship

Ketamine prescribing requires an established prescriber-patient relationship and a legitimate clinical basis for the prescription. A clinician cannot prescribe ketamine to a patient they have not evaluated — the standard requirements for any controlled substance prescription apply. Telehealth prescribing of ketamine emerged significantly during and after the COVID-19 public health emergency, when DEA waived certain in-person requirements. The status of those waivers has continued to evolve; clinicians who want to prescribe ketamine via telehealth should confirm current DEA and state requirements before doing so.

The Ryan Haight Act requires an in-person evaluation before prescribing controlled substances via telemedicine in most circumstances. DEA has issued rules and proposed additional rules addressing ketamine-specific telehealth prescribing that were in a state of ongoing regulatory development as of early 2026. A clinician who wants to offer ketamine through a telehealth model should get current legal advice on the applicable requirements.

Ketamine and psychedelic-assisted therapy

Ketamine’s mechanism of action — primarily NMDA receptor antagonism rather than serotonin 5-HT2A agonism — is pharmacologically distinct from classical psychedelics like psilocybin and MDMA. However, at subanesthetic doses, ketamine produces dissociative and, at higher doses, psychedelic-like experiences that some practitioners incorporate into a therapeutic framework involving preparation and integration sessions.

This psychedelic-assisted model for ketamine — distinct from standard infusion clinic practice — is not separately regulated by OPS or any state psychedelic program. It operates within the standard off-label prescribing framework. The legal considerations for a clinician who structures ketamine treatment with preparation and integration support are the same as for any ketamine practice, with the additional consideration that the expanded therapeutic model may create additional standard of care questions about what the preparation and integration component involves and who provides it.

When public information may be enough

The Spravato REMS program requirements are published by the FDA at fda.gov. DEA registration requirements are at dea.gov/drug-registration. ASKP3 publishes practice guidance at askp3.org. The APA’s position statement on ketamine is publicly available at psychiatry.org. State prescribing authority requirements are available through state medical and nursing board websites.

When you should speak with a lawyer

A clinician who wants to open a ketamine clinic — whether esketamine, IV ketamine, or both — should consult an attorney familiar with FDA REMS requirements, DEA controlled substance regulations, and state scope of practice and facility licensing before establishing the practice. A clinician who offers ketamine and has received a patient complaint, a board inquiry, or a malpractice demand should retain counsel before responding. A clinician who wants to offer ketamine via telehealth should get current legal advice on DEA and state requirements before prescribing.

You might also want to read

This article is for general informational purposes only and does not constitute legal or medical advice. Regulatory requirements for ketamine prescribing change frequently. For advice specific to your practice, consult a licensed attorney and appropriate clinical authorities.